Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

References

• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• KardosPVogelmeierCBuhlRCriéeCPWorthHThe prospective non-interventional DACCORD study in the National COPD Registry in Germany: design and methodsBMC Pulm Med2015151225578330
   PubMed Web of Science ®Google Scholar
• BuhlRCriéeCPKardosPA year in the life of German patients with COPD: the DACCORD observational studyInt J Chron Obstruct Pulmon Dis20161111639164627499620
   PubMed Web of Science ®Google Scholar
• VogelmeierCWorthHBuhlR“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORDInt J Chron Obstruct Pulmon Dis20171248749428203072
   PubMed Web of Science ®Google Scholar
• WorthHBuhlRCriéeCPKardosPMailänderCVogelmeierCThe ‘real-life’ COPD patient in Germany: the DACCORD studyRespir Med2016111647126775251
   PubMed Web of Science ®Google Scholar
• KardosPVogelmeierCWorthHA two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational studyRespir Med2017124576428284322
   PubMed Web of Science ®Google Scholar
• WorthHBuhlRCriéeC-PKardosPLossiNSVogelmeierCFGOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational studyRespir Med201720171317784
   Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol–glycopyrronium versus salmeterol–fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• LandsbergerHAHawthorne RevisitedNew YorkThe New York State School of Industrial and Labor Relations1958
   Google Scholar
• McCarneyRWarnerJIliffeSvan HaselenRGriffinMFisherPThe Hawthorne effect: a randomised, controlled trialBMC Med Res Methodol2007713017608932
   PubMed Web of Science ®Google Scholar
• JonesPWGelhornHWilsonHEffect of bronchodilator and placebo therapy on SGRQ score in patients over 3 years: difference between low/medium and high socio-economic countriesAm J Respir Crit Care Med2014189A5962.s
   Web of Science ®Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysisRespir Res20131410024093477
   PubMed Web of Science ®Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis20151012207221726527869
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
   PubMed Web of Science ®Google Scholar
• ChalmersJDPooleCWebsterSTebbothADickinsonSGayleAAssessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD)Respir Res20181916329642882
   PubMed Web of Science ®Google Scholar
• ChapmanKRHurstJRFrentSMLong-term triple therapy de-escalation to indacaterol/glycopyrronium in COPD Patients (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med Epub2018520
   Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDThorax201671211812526585525
   PubMed Web of Science ®Google Scholar
• LeighRPizzichiniMMMorrisMMMaltaisFHargreaveFEPizzichiniEStable COPD: predicting benefit from high-dose inhaled corticosteroid treatmentEur Respir J200627596497116446316
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease2018 Available from: www.goldcopd.orgAccessed December 12, 2017
   Google Scholar
• HoritaNGotoAShibataYLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)Cochrane Database Syst Rev20172CD01206628185242
   PubMed Web of Science ®Google Scholar